MV522人肺癌細(xì)胞、MV52 返回列表頁(yè)

MV522 人肺癌細(xì)胞
Catalogue No.: C1506
Product Format: a T25 flask
Culture Properties：貼壁
Complete Growth Medium: 89%1640+10%FBS+1%雙抗
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Application: Cells and cancer research
NOTE: FOR RESEARCH USE ONLY.

Components

167 oncology drug approvals since 1998, the year the first CDx test for Herceptin was approved. The great majority of CDx tests are for drukl that inhibit signal transduction pathways by either inhibiting the intracellular kinase activity with a small molecule or preventing ligand-induced receptor activation with a monoclonal antibody. In most of these cases, prospective patient selection for the biomarker-positive subpopulation was